In celebration of the authorization of Phase 2b/3 for JointStem
First of all, I wish you health and peace. Thanks to your support and encouragement, Phase 2b/3 of the clinical test for JointStem has been authorized.
Read moreFirst of all, I wish you health and peace. Thanks to your support and encouragement, Phase 2b/3 of the clinical test for JointStem has been authorized.
Read moreK-Stem Cell, Co., Ltd., a bio company specializing in adult stem cells, announced on the 15th that it received the notification of patent registration of its “Culture media and methods for culturing mesenchymal stem cell” from Japan and Singapore (Application No. in Japan: 2013-52064; Application No. in Singapore: 201300377-7).
Read moreR-Japan, a Japanese affiliate of K-Stem Cell, Co., Ltd, a bio company specializing in adult stem cell, announced on the 12th that it filed the application for ‘production license for processed cell’ under the Japanese Regenerative Medicine Promotion Act.
Read moreBiostar, the adult stem cell bank co-managed by Nature Cell that represents Korea, announced its decision to spur its placental stem cell storage business..
Read moreK-Stem Cell, a bioscience enterprise specializing in adult stem cell technology, made an announcement that the patent for the “method of preventing the disintegration and aggregation of stem cells and the constituents thereof (Patent Registration No. 10-1467481),” for which the application process was completed in 2013, was accepted for registration by the Korean Intellectual Property Office (KIPO) on November 25, 2014.
Read moreK-Stem Cell (formerly, RNL Bio), a bioscience enterprise, announced that the patent for the “method of manufacturing stem cells in an appropriate size for intravascular administration(Patent Application No. 10-2012-0040488),” for which the application process was completed in 2012, was accepted for registration by the Korean Intellectual Property Office (KIPO) on November 20, 2014.
Read more
Most Commented